Alvotech
ALVO Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 23, 2026
$4.58
KIRA · Stoqly’s AI analyst, in plain words
- Alvotech had $586M of revenue in fiscal 2025, up 19.7% on the year before. Over five years, revenue changed +54.5% a year on average.
- Its operating margin was 13.3%, down 0.9 pts: of every 100 in sales, about 13 is left after running the business.
- Alvotech made $27.9M of net profit in fiscal 2025.
- Free cash flow was −$115M in fiscal 2025, −19.6% of revenue.
- Alvotech returned $0.0M to shareholders in fiscal 2025. The diluted share count rose 8.7%.
- Alvotech owes $1.1B more than it holds in cash, about 9.7 years of operating profit.
Market cap
$1.3B
P/E
45.8x
Revenue
$586M
Net income
$27.9M
Free cash flow
−$115M
Operating margin
13.3%
Alvotech in 30 seconds · fiscal 2025
Are sales growing?
+19.7%
Yes. Sales grew 19.7% last year.
Does it make a profit?
4.8%
A little. It keeps 4.8% of every sale as profit.
Does profit turn into cash?
−19.6%
No. It spent more cash than it brought in.
Is debt under control?
9.7x
Heavy. Repaying its debt would take 9.7 years of operating profit.
How healthy are the accounts?
3 / 9
Weak. It passes 3 of 9 health tests.
How is the share priced?
45.8x
One share costs 45.8 times its yearly profit per share.
What Alvotech does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 20-F · Mar 31, 2026
- Legal name
- Alvotech
- CIK
- 0001898416
Alvotech · ALVO
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $36.8M | $83.0M | $91.4M | $490M | $586M |
| Revenue growth | −44.8% | 125.8% | 10.1% | 435.6% | 19.7% |
| Gross margin | 100.0% | 22.8% | −75.9% | 62.2% | 59.8% |
| Operating margin | −640.3% | −417.3% | −388.1% | 14.2% | 13.3% |
| Net income | −$102M | −$514M | −$552M | −$232M | $27.9M |
| Net margin | −276.0% | −618.6% | −603.4% | −47.3% | 4.8% |
| Diluted EPS | −$0.92 | −$2.60 | −$2.43 | −$0.87 | $0.10 |
| Cash | |||||
| Cash from operations | −$228M | −$312M | −$312M | −$237M | −$50.2M |
| Capital expenditure | $20.5M | $37.9M | $33.2M | $53.7M | $64.5M |
| Free cash flow | −$249M | −$350M | −$345M | −$291M | −$115M |
| FCF margin | −676.1% | −421.9% | −377.8% | −59.3% | −19.6% |
| Dividends paid | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Share count change | 18.2% | 78.7% | 14.9% | 17.9% | 8.7% |
| Debt and strength | |||||
| Cash and short-term investments | $17.6M | $66.4M | $11.2M | $51.4M | $172M |
| Debt incl. finance leases | $401M | $765M | $960M | $1.1B | $1.3B |
| Shareholders' equity | −$136M | −$564M | −$932M | −$413M | −$284M |
| Net debt / EBITDA | — | — | — | 10.1x | 9.7x |
| Current ratio | 1.1x | 1.4x | 0.7x | 2.4x | 1.9x |
| Interest coverage | −2.0x | −1.8x | −1.3x | 0.2x | 0.5x |
| Returns and quality | |||||
| Return on capital | −75.1% | −204.7% | −1,698.1% | 9.1% | 6.0% |
| Piotroski F-score | — | 3 | 2 | 5 | 3 |
| Altman Z'' | −9.0 | −9.2 | −11.1 | −5.0 | −3.9 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Alvotech · ALVO
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $4.58 a share, the company is worth $1.3B: 45.8 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0001898416). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.